RecruitingPhase 1NCT05010564
Blood
B-cell chronic lymphocytic leukemia
219
studies recruiting now
as of 7 Sept 2026
2,305
studies registered in total
as of 7 Sept 2026
17
countries with a recruiting site
as of 7 Sept 2026
20 Oct 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 3NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RecruitingPhase 2NCT06812715
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
RecruitingPhase 1 / Phase 2NCT04588922
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 219 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new B-cell chronic lymphocytic leukemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About B-cell chronic lymphocytic leukemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (P2RX7, IGHV3-21, ATM, CCND1, TP53, ARL11).
Treatments being studied
16 approved treatments and 161 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Fludarabine Phosphate (Fludara)Approved: AcalabrutinibApproved: Venetoclax (Venclexta)Approved: Zanubrutinib (Brukinsa)Approved: Alemtuzumab (Campath mabcampath)Approved: Ibrutinib (Imbruvica)Approved: Bendamustine Hydrochloride (Belrapzo)Approved: Acalabrutinib Maleate (Calquence)Approved: Ofatumumab (Arzerra)Approved: Obinutuzumab (Gazyvaro)Approved: Chlorambucil (Leukeran)Approved: Idelalisib (Zydelig)Approved: Duvelisib Monohydrate (Copiktra)Approved: DuvelisibApproved: Pirtobrutinib (Jaypirca)Approved: Rituximab (Blitzima)
Phase 3Orelabrutinib (Innobruka)
Phase 3Tisagenlecleucel (Kymriah)
Phase 3Umbralisib Tosylate (Ukoniq)
Phase 3Alvocidib
Phase 3Fludarabine
Phase 3Methylprednisolone (Medrol)
Phase 3Cladribine (Cladribine)
Phase 3Nemtabrutinib
+ 153 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).